Expression of TNF-α, tristetraprolin, T-cell intracellular antigen-1 and Hu antigen R genes in synovium of patients with rheumatoid arthritis

International Journal of Molecular Medicine

Volumn 18, Issue 2, 2006, Pages 273-278

  Suzuki, Eiji ^a,b   Tsutsumi, Akito ^a   Sugihara, Makoto ^a   Mamura, Mizuko ^a   Goto, Daisuke ^a   Matsumoto, Isao ^a   Ito, Satoshi ^a   Ikeda, Kotaro ^a   Ochiai, Naoyuki ^a   Sato, Yukio ^b   Sumida, Takayuki ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

^b FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

Author keywords

AU rich element; Hu antigen R; Rheumatoid arthritis; T cell intracellular antigen 1; Tristetraprolin

Indexed keywords

ELAV-LIKE PROTEIN 1; HUR PROTEIN; MEMBRANE ANTIGEN; POLYADENYLIC ACID BINDING PROTEIN; RNA BINDING PROTEIN; TIA1 PROTEIN, HUMAN; TRISTETRAPROLIN; TUMOR NECROSIS FACTOR ALPHA; ZFP36 PROTEIN, HUMAN;

AGED; ARTICLE; GENETICS; HUMAN; METABOLISM; MIDDLE AGED; OSTEOARTHRITIS; PHYSIOLOGY; RHEUMATOID ARTHRITIS; SYNOVIUM;

AGED; ANTIGENS, SURFACE; ARTHRITIS, RHEUMATOID; HUMANS; MIDDLE AGED; OSTEOARTHRITIS; POLY(A)-BINDING PROTEINS; RNA-BINDING PROTEINS; SYNOVIAL MEMBRANE; TRISTETRAPROLIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34547455485     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Laura PH and Barton FH: Pathology of rheumatoid arthritis and associated disorders. In: Arthritis and Allied Conditions: A Textbook of Rheumatology. Koopman WJ (ed). 13th edition. Williams & Wilkins, Baltimore, MD, pp993-1016, 1997.
2. Szekanecz Z and Koch AE: Cytokines. In: Kelley's Textbook of Rheumatology. Ruddy S, Harris ED and Sledge CB (eds). 6th edition. W. B. Sanders Com., Philadelphia, PA, pp275-290, 2001.
3. Keffer J, Probrt L, Cazlaris H, et al: Transgenic mice expressing human tumor necrosis factor: a predictive genetic model of arthritis. EMBO J 13: 4025-4031, 1991.
4. Tak PP and Firestein GS: NF-kappa B: a key role in inflammatory disease. J Clin Invest 107: 7-11, 2001.
5. Palanki MS: Inhibition of AP-1 and NF-kappa B mediated transcriptional activation: therapeutic potential in autoimmune diseases and structural diversity. Curr Med Chem 9: 219-227, 2002.
6. Clark A: Post-transcriptional regulation of pro-inflammatory gene expression. Arthritis Res 2: 172-174, 2000.
7. Anderson P, Phillip K, Stoecklin G and Kedersha N: Posttranscriptional regulation of proinflammatory proteins. J Leukoc Biol 76: 42-47, 2004.
8. Blackshear PJ: Tristetraprolin and other CCCH tandem zincfinger proteins in the regulation of mRNA turnover. Biochem Soc Trans 30: 945-952, 2002.
9. Taylor GA, Carballo E, Lee DM, et al: A pathogenetic role for TNF alpha in the syndrome of cachexia, arthritis, and autoimmunity resulting from tristetraprolin deficiency. Immunity 4: 445-454, 1996.
10. Dember LM, Kim ND, Liu KQ and Anderson P: Individual RNA recognition motifs of TIA-1 and TIAR have different RNA binding specificities. J Biol Chem 271: 2783-2788, 1996.
11. Kedersha N and Anderson P: Stress granule: sites of mRNA triage that regulate mRNA stability and translatability. Biochem Soc Trans 30: 963-969, 2002.
12. Piecyk M, Wax S, Beck ARP, et al: TIA-1 is a translational silencer that selectively regulates the expression of TNF-alpha. EMBO J 19: 4154-4163, 2000. (Pubitemid 30608553)
13. Atasoy U, Watson J, Patel D and Keene JD: ELAV protein HuA (HuR) can redistribute between nucleus and cytoplasm and is upregulated during serum stimulation and T cell activation. J Cell Sci 111: 3145-3156, 1998. (Pubitemid 28532425)
14. Fan XC and Steitz JA: Overexpression of HuR, a nuclearcytoplasmic shuttling protein, increases the in vivo stability of ARE-containing mRNAs. EMBO J 17: 3448-3460, 1998.
15. Peng SS, Chen CY, Xu N and Shyu AB: RNA stabilization by AU-rich element binding protein, HuR, an ELAV protein. EMBO J 17: 3460-3470, 1998.
16. Tsutsumi A, Suzuki E, Adachi Y, et al: Expression of tristetraprolin (G0S24) mRNA, a regulation of tumor necrosis factor-alpha production, in synovial tissues of patients with rheumatoid arthritis. J Rheumatol 31: 1044-1049, 2004.
17. Arnett FC, Edworthy SM, Bloch DA, et al: The American rheumatism association 1987 revise criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31: 315-323, 1988.
18. Taylor PC: Anti-TNF-alpha therapy for rheumatoid arthritis: an update. Intern Med 42: 15-20, 2003.
19. Shanahan JC and St. Clair W: Short analytical review. Tumor necrosis factor alpha blockade: a novel therapy for rheumatic disease. Clin Immunol 103: 231-242, 2002.
20. Fernandes JC, Martel-Pelletier J and Pelletier JP: The role of cytokines in osteoarthritis pathphysiology. Biorheology 39: 237-246, 2002.
21. Dean JL, Wait R, Mahtani KR, Sully G, Clark AR and Saklatvala J: The 3' untranslated region of tumor necrosis factor alpha mRNA is target of the mRNA-stabilizing factor HuR. Mol Cell Biol 21: 721-730, 2001.
22. Zhang T, Kruys V, Huez G and Gueydan C: AU-rich element-mediated translation control: complexity and multiple activities of trans-activating factors. Biochem Soc Trans 30: 952-958, 2002. (Pubitemid 36002387)
23. Dean JL, Sully G, Clark AR and Saklatvala J: The involvement of AU-rich element-binding proteins in p38 mitogen-activated protein kinase pathway-mediated mRNA stabilization. Cell Signal 16: 1113-1121, 2004.
24. Tchen CR, Brook M, Saklatvala J and Clark AR: The stability of tristetraprolin mRNA is regulated by mitogen-activated rotein kinase p38 and by tristetraprolin itself. J Biol Chem 279: 32393-32400, 2004.
25. Dixon DA, Blach GC, Kedersha N, et al: Regulation of cyclooxygenase- 2 expression by the translational silencer TIA-1. J Exp Med 198: 475-481, 2003.